In a rare mis­fire, Re­gen­eron scraps its RSV drug af­ter a PhI­II fail­ure

In a rare Phase III fail­ure, Re­gen­eron says its late-stage an­ti­body for RSV — sup­tavum­ab (REGN2222) — flopped in a ma­jor study which en­rolled more than a thou­sand healthy pre-term in­fants.

There won’t be a sec­ond act for this drug. Re­gen­eron $REGN is scrap­ping the drug, once held up as one of its top Phase III prospects, and mov­ing on.

Al­though re­searchers were able to tease out ev­i­dence of ef­fi­ca­cy in one sub­group, they say the drug failed to sig­nif­i­cant­ly re­duce the num­ber of med­ical­ly-at­tend­ed RSV in­fec­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.